Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts vigorous 13% annual growth in the neuropathic pain market between 2005 and 2010, with continued 8% annual growth between 2010 and 2015.

The new Pharmacor report Neuropathic Pain finds that market growth during the 2005 to 2015 study period in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan will be the result of a steady influx of newly approved drugs to treat the highly underserved markets of painful diabetic neuropathy, postherpetic neuralgia, and HIV-related neuropathic pain. Antiepileptic agents will emerge as the most lucrative class of drugs to treat neuropathic pain, and growth will be driven through 2015 by Pfizer's Lyrica and Neurontin as well as antiepileptic drugs from Depomed, Xenoport/GSK, and Schwarz/UCB.

The report also finds that, despite the success of Lyrica and Eli Lilly's antidepressant Cymbalta, the neuropathic pain market continues to be distinguished by immense unmet need and significant opportunity for drug developers.

"Experts indicate that the most important need in this market is for mechanism-based treatment approaches, and they say that such an advancement would revolutionize this segment of the pain arena," said Decision Resources Analyst Maria Marzilli. "We forecast that Lyrica will overtake its predecessor, Neurontin, as the patient share and sales leader by 2015 -- however, even Lyrica is plagued by a lack of efficacy for neuropathic pain."

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  All company, brand, or product names contained in this document may be      trademarks or registered trademarks of their respective holders.     For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Most Promising Emerging Agents for Metabolic Syndrome are from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Lilly

View Now